These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11366972)

  • 1. Taking a break when all else fails.
    Gilden D
    GMHC Treat Issues; 1999 Apr; 13(4):1-3. PubMed ID: 11366972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. For people needing a new drug.
    Vazquez E
    Posit Aware; 1999; 10(2):45-6. PubMed ID: 11366852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
    J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatment options.
    Fornataro K; Jefferys R
    Body Posit; 1999 Jun; 12(6):11-2. PubMed ID: 11367013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient adherence, not viral load now most important in HIV therapy.
    Rep Med Guidel Outcomes Res; 2000 Feb; 11(3):6-7. PubMed ID: 11768406
    [No Abstract]   [Full Text] [Related]  

  • 8. ICAAC and Hamburg: Part 1. Schmuddelwetter or, rating protease inhibitors on the pass/fail system.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1997 Dec; 3(12):29-37. PubMed ID: 11364943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Another take on when to start and how to succeed.
    Friedland GH
    AIDS Clin Care; 2001 Sep; 13(9):82. PubMed ID: 11547600
    [No Abstract]   [Full Text] [Related]  

  • 10. Salvage solitaire (or, HAART takes a holiday).
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1999 Jul; 5(7):10-23. PubMed ID: 11367132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Salvage therapy in HIV disease].
    Ajisawa A
    Nihon Rinsho; 2002 Apr; 60(4):745-9. PubMed ID: 11968782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The latest antiviral news.
    Vazquez E
    Posit Aware; 1999; 10(2):44. PubMed ID: 11366851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somewhere over the rainbow...
    Gilden D
    GMHC Treat Issues; 1997 Feb; 11(2):1-4. PubMed ID: 11364105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New knowledge and new challenges: 4th National Conference on Retroviruses & Opportunistic Infections].
    Agosto M; Ehara R
    Sidahora; 1997; ():18-21. PubMed ID: 11364490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype.
    Izopet J; Souyris C; Sandres-Sauné K; Puissant B; Obadia M; Pasquier C; Puel J; Blancher A; Massip P
    J Med Virol; 2002 Nov; 68(3):305-10. PubMed ID: 12226815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
    Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.